{
    "nctId": "NCT02934269",
    "officialTitle": "A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects",
    "inclusionCriteria": "* Healthy male and/or female subjects between the ages of 18 and 55 years, and a body mass index (BMI) of \u2265 18 and \u2264 33 kg/m2 with body weight \u2265 50 and \u2264 90 kg at screening.\n* Females must have been surgically sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingo-oophorectomy; proper documentation required) at least 6 months before screening, or be postmenopausal (defined as 24 consecutive months without menses before screening, with a follicle-stimulating hormone \\[FSH\\] level of \\> 40 IU/L at screening).\n* Must have minimum age of 18 Years\n* Must have maximum age of 55 Years",
    "exclusionCriteria": "* Exposure/treatment to an investigational (new chemical entity) or marketed drug or biologic within 30 days preceding the first dose administration, or five half-lives of that investigational drug or biologic, if known (whichever is longer).\n* Donation blood or serum within 8 weeks before the first dose administration to a blood bank or blood donation center.\n* History of alcohol or drug abuse (as defined by the current version of the DSM) within 2 years before the first dose administration, or positive alcohol or drug screen.\n* Vaccination within 30 days prior to the first dose administration or has plans to receive a vaccination during the course of the study (including the follow phone call on Day 105)."
}